Top 20 Facts About OZEMPIC WEIGHT LOSS (2022) – Ozempic is not licensed for weight reduction, however it is used off label to help persons with Type 2 diabetes and cardiovascular risk lose weight.
List Of Top 20 Facts About OZEMPIC WEIGHT LOSS (2022):
Ozempic (semaglutide) is a pre-filled injectable pen approved by the Food and Drug Administration in 2017 to help people with Type 2 diabetes mellitus manage their blood sugar levels and to reduce the risk of major adverse cardiovascular events in people with Type 2 diabetes and established cardiovascular disease. Ozempic is a pharmaceutical manufactured by Novo Nordisk that belongs to a therapeutic family known as glucagon-like peptide 1 (GLP-1) receptor agonists, which are non-insulin therapies for persons with Type 2 diabetes. It is not intended to treat Type 1 diabetic patients.
The most prevalent kind of diabetes is type 2 diabetes, which is caused by insulin resistance. Type 2 diabetes, unlike Type 1 diabetes, develops later in life, and obesity is a substantial risk factor. Diabetes drugs are vital for controlling blood sugar levels and relieving symptoms, but so is maintaining a healthy weight. Ozempic is one diabetic medicine that helps individuals lose weight. This article will go through how to use Ozempic for weight reduction, including its efficacy, safety, and alternatives.
Semaglutide consistently exhibited blood sugar management and weight loss in people with Type 2 diabetes and obesity in the SUSTAIN clinical trials. Ozempic has been shown to suppress appetite and food cravings. It also reduced the relative desire for fatty, energy-dense meals. These findings were extremely relevant in persons with Type 2 diabetes since maintaining a healthy body weight is critical for diabetes treatment. In rare cases, with correct weight management, the body’s capacity to control blood sugar may even return to normal.
Aside from diabetes treatment, further studies were undertaken to focus on Ozempic and weight reduction. The Semaglutide Treatment Effect in Adults with Obesity (STEP) research looked at people who were either overweight or obese and did not have diabetes. The trial employed 2.4 mg semaglutide once weekly. The results revealed a 14.9 percent weight decrease from baseline after 68 weeks (approximately 16 months) with semaglutide plus lifestyle adjustments. More precisely, almost 70% of participants dropped at least 10% of their body weight, approximately 50% lost at least 15% of their body weight, and approximately 33% lost at least 20% of their body weight. For comparison, one to three years following a sleeve gastrectomy (a kind of bariatric surgery), there is an average 20% to 30% weight loss.
These findings are significant since a 10% to 15% (or greater) weight loss is suggested in overweight and obese adults with related comorbidities (such as prediabetes, hypertension, and obstructive sleep apnea). The current study results indicate that semaglutide can meet the recommended aim of weight loss and obesity therapy.
Ozempic administration may be preferred to other weight-loss drugs since it is administered as a once-weekly injection as opposed to some other treatments’ daily, twice-day, or three-times-daily dosing.
Ozempic was also well tolerated in investigations. The most prevalent adverse effects were gastrointestinal, such as nausea, constipation, and diarrhea, which were usually mild-to-moderate in intensity.
Ozempic is currently approved for use solely in persons with Type 2 diabetes mellitus to improve blood sugar management and lower the risk of significant adverse cardiovascular events in people with both Type 2 diabetes and cardiovascular disease.
Despite not being licensed for weight reduction, some healthcare providers have begun using Ozempic off-label for weight loss due to the impressive findings of scientific research. Ozempic, on the other hand, should not be utilized for everyone. Ozempic should not be used in patients who have a personal or family history of medullary thyroid carcinoma (a kind of cancer) or who have multiple endocrine neoplasia syndrome type 2.
Before using Ozempic, keep it in the refrigerator between 36 and 46 degrees Fahrenheit. Pre-filled Ozempic pens should not be frozen. After the initial use, the pen can be stored at regulated room temperature (59 degrees to 86 degrees Fahrenheit) or in a refrigerated for 56 days. When not in use, keep the pen cap on. The enclosures should be kept away from direct sunshine and extreme heat.
While Ozempic is not known to interact with alcohol, excessive alcohol consumption can reduce blood sugar. Monitoring low blood sugar levels is critical for diabetics to avoid hypoglycemic symptoms (low blood glucose).
Furthermore, Ozempic may raise the risk of pancreatitis (inflammation of the pancreas). Pancreatitis can also be exacerbated by excessive alcohol intake. Heavy alcohol consumption should be avoided when taking Ozempic to help prevent pancreatitis.